Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameJacobio-B
Stock Code01167
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities臨床階段製藥公司,專注於創新腫瘤療法的自主發現和開發,主要開發變構SHP2抑制劑、KRAS抑制劑等小分子候選藥物。
Listing Date2020-12-21
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國北京市北京經濟技術開發區科創六街88號F2樓
Business Address (Hong Kong)香港灣仔皇后大道東248號陽光中心40層
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.jacobiopharma.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 14.00 / shares
Offer Price RangeFinal offer price only, no range
Lot Size300 shares
Entry ThresholdHK$ 4,200
Par ValueTo be extracted
Offer Period2020-12-09 to 2020-12-14
Global Offering Shares96,476,100 shares
HK Public Offer Shares (Initial)9,648,000 shares (10.0%)
Public Offer Lots (Initial)32,160lots (Pool A16,080lots,Pool B16,080lots)
International Placing Shares (Initial)86,828,100 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO759,653,880 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share34.4%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 1,350,665,400

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 300 HK$ 4,200
2 lots 600 HK$ 8,400
3 lots 900 HK$ 12,600
4 lots 1,200 HK$ 16,800
5 lots 1,500 HK$ 21,000
6 lots 1,800 HK$ 25,200
7 lots 2,100 HK$ 29,400
8 lots 2,400 HK$ 33,600
9 lots 2,700 HK$ 37,800
10 lots 3,000 HK$ 42,000
15 lots 4,500 HK$ 63,000
20 lots 6,000 HK$ 84,000
25 lots 7,500 HK$ 105,000
30 lots 9,000 HK$ 126,000
35 lots 10,500 HK$ 147,000
40 lots 12,000 HK$ 168,000
45 lots 13,500 HK$ 189,000
50 lots 15,000 HK$ 210,000
100 lots 30,000 HK$ 420,000
150 lots 45,000 HK$ 630,000
200 lots 60,000 HK$ 840,000
250 lots 75,000 HK$ 1,050,000
300 lots 90,000 HK$ 1,260,000
350 lots 105,000 HK$ 1,470,000
400 lots 120,000 HK$ 1,680,000
450 lots 135,000 HK$ 1,890,000
500 lots 150,000 HK$ 2,100,000
1,000 lots 300,000 HK$ 4,200,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1,500 lots 450,000 HK$ 6,300,000
2,000 lots 600,000 HK$ 8,400,000
2,500 lots 750,000 HK$ 10,500,000
3,000 lots 900,000 HK$ 12,600,000
3,500 lots 1,050,000 HK$ 14,700,000
4,000 lots 1,200,000 HK$ 16,800,000
4,500 lots 1,350,000 HK$ 18,900,000
5,000 lots 1,500,000 HK$ 21,000,000
7,000 lots 2,100,000 HK$ 29,400,000
9,000 lots 2,700,000 HK$ 37,800,000
13,000 lots 3,900,000 HK$ 54,600,000
16,080 lots 4,824,000 HK$ 67,536,000

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
Avg Daily HK Mkt Cap HK$ 4.35B
Est. Threshold HK$ 9.71B
Analysis Result HK market cap below threshold, need +123%

Valuation & Financials

Market Cap (at Offer Price)HK$ 10,635,154,320
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不適用(公司處於虧損狀態)
Profit/Loss Status截至2019年12月31日止年度,虧損人民幣425.8百萬元
Period-End Cash Balance人民幣314.3百萬元
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Balance Sheet
Item 201820192020
Cash and cash equivalents 420,833314,338405,481
Total current assets 425,031318,084414,451
Total assets 473,596363,327455,723
Total current liabilities 17,96545,72134,316
Total liabilities 570,841833,4051,738,898
Total equity -97,245-470,078-1,283,175
Equity attributable to owners -95,365-469,809-1,283,189
Cash Flow Statement
Item 20182019
Net cash from operating activities -79,893-113,025
Net cash from investing activities 14,584-273
Net cash from financing activities 356,827929
Net increase in cash 291,518-112,369
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 14.42
First Day OpenHK$ 15.98
First Day Change3.00%
First Day Volume63740700.0
First Day Turnover1022840000.0
Use of Proceeds
1、約88.0%,或143.4百萬美元(1,111.5百萬港元),將主要用于產品的臨床開發及商業化; 2、約8.0%,或13.0百萬美元(101.0百萬港元)將用于建造符合GMP標準的內部生產設施; 3、約4.0%,或6.5百萬美元(50.5百萬港元)將用于我們的一般企業及營運資金用途。

Underwriting Syndicate

Joint Sponsors (2)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894
Overall Coordinators (2)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894
Joint Bookrunners (2)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894
Joint Lead Managers (2)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 HBC Asia Healthcare Opportunities V LLC 77,515,200 HKD — 5.74% — 6 months 2021-06-21
2 LAV Prime Limited 116,272,800 HKD — 8.61% — 6 months 2021-06-21
3 Matthews Asia Funds 116,272,800 HKD — 8.61% — 6 months 2021-06-21
4 Octagon Investments Master Fund LP 77,515,200 HKD — 5.74% — 6 months 2021-06-21
5 Sage Partners Master Fund 38,757,600 HKD — 2.87% — 6 months 2021-06-21
6 Superstring Capital Master Fund LP 38,757,600 HKD — 2.87% — 6 months 2021-06-21

Directors & Management

PositionChinese nameEnglish Name
Chairman王印祥—
Company Secretary薛青、楊靜文—
No director data available.

Major Shareholders

Major Shareholders & Holdings王印祥及其一致行動人士持股約36.48%;BioEngine Capital Holding Limited持股約12.94%;晟德大藥廠股份有限公司持股約15.64%;Qiming Venture Partners相關基金合計約10.77%;HH SPR-III Holdings Limited約7.49%。
About this page

This page shows Jacobio-B (01167) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect